F. (2001). Attitudes and use of alternative therapies in UK prostate cancer patients - isn't time we were in the know? Prostate Cancer Prostatic Dis, 4, 235-241Cheetham PJ, Le Monnier KJ, Brewster SF (2001) Attitudes and use of alternative therapies in UK prostate cancer patients-isn't...
Prostate cancer is the most common cancer in men in the UK, accounting for almost a quarter of male cancers. Each year, nearly 32,000 men in the UK are diagnosed, and more than 10,000 die from the disease. Men have a one in 14 lifetime risk of developing prostate cancer. Cases are...
‘hands off’ approach in the follow-up process. Patients did not feel they saw their GP any more frequently after discharge and they rarely discussed their prostate cancer. If PSA testing was conducted, it was often carried out by the practice nurse and the patient may not see the GP at...
Reliable prognostic biomarkers to distinguish indolent from aggressive prostate cancer (PCa) are lacking. Many studies investigated microRNAs (miRs) as PCa prognostic biomarkers, often reporting inconsistent findings. We present a systematic review of th
With an increasing 35,000 new cases a year, Professor Baker points out prostate cancer is the most widespread cancer among men in the UK. Surveys have reported that in general, prostate cancer patients rated their experiences of care less favorably than patients with other cancers. He indicates...
Prostate cancer, disease characterized by uncontrolled growth of cells within the prostate gland. Prostate cancer is a frequently diagnosed cancer among males. Learn more about the causes, symptoms, and treatment of prostate cancer.
byCancer Research UK Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0 A prostate cancer drug won't be offered on the NHS any earlier in the treatment plans of patients living with the disease in England, after it failed...
The pilot was the first ever in the UK to assessgenetic screeningfor prostate cancer in the general population, and will now be followed by a larger-scale study that could prove the potential of a new screening program for the disease. ...
Cancer immunotherapies such as bispecific T-cell engagers have seen limited adoption in prostate cancer (PC), possibly due to differing levels of cancer receptor expression and effector T-cell infiltration between patients and inherent defects in T-cell engager design. Methods CD8+ T-cell infiltration...
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection c